n=714 rate ratio 1.41, 95% confidence interval 1.08-1.83

Common and differential alterations of general emotion processing in obsessive-compulsive and social anxiety disorder

t2 sensitive brain abnormalities fmri analysis

diameter 10 mm, 515 mm3, centre x, y, z=7/-7, 26, 24
diameter 20 mm, 4169 mm, centre x, y, z=0, 44, -2

Diagnostic accuracy of a brief screening tool for attention deficit hyperactivity disorder in UK prison inmates

Distinct neurobiological signatures of brain connectivity in depression subtypes during natural viewing of emotionally salient films

Dual neurocircuitry dysfunctions in disruptive behavior disorders: emotional responding and response inhibition

256 times 256 acquisition matrix fmri analysis
emotion whole brain repeated measures anova

TR=8.1 ms; TE=3.2 ms, flip angle 20°; FOV=240 mm, 128

Feedback learning and behavior problems after pediatric traumatic brain injury

prevent chance level performances of contaminating analysis

GCS=12-3, LOC duration>30 min, PTA duration>1 h; n=37
Cronbach's alpha>0.90; Verhulst & van der Ende, 2013

Learning to trust: trust and attachment in early psychosis

reality 2 probabilistic computer algorithms

subscale alpha=0.79 avoidance subscale alpha=0.67

Lifetime prevalence of non-suicidal self-injury in patients with eating disorders: a systematic review and meta-analysis

pooled nssi proportion estimates meta analysis
generate 95% binomial confidence interval

Multidimensional assessment of impulsivity in schizophrenia, bipolar disorder, and major depressive disorder: testing for shared endophenotypes

Neighbourhood characteristics and the incidence of first-episode psychosis and duration of untreated psychosis

Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories

MADRS<10 Diazgranados et al. 2010a Zarate et al. 2012
studies=2, non ketamine NMDAR antagonists=27.0%
studies=2, non ketamine NMDAR antagonists=16.2%
studies=2, non ketamine NMDAR antagonists=12.3% v. placebo=20.0%; RR=0.92, 95% CI 0.11-8.09, p=0.94
studies=2, non ketamine NMDAR antagonists=11.1% v. placebo=20.0%; RR=0.62, 95% CI 0.14-2.66, p=0.52